Healthcare Wrap: Cann Group, OncoSil and Imugene Power a Big Week

Cann Group (ASX:CAN) led the sector with a 50.00% weekly gain after it moved to clean up its balance sheet. The company agreed to redeem its outstanding convertible notes early at face value, while also adding $2 million to its private credit facility to fund that move. Investors cared because convertible notes can turn into shares later and dilute existing holders. Removing them can simplify the capital structure, even if debt is still part of the picture.

OncoSil Medical (ASX:OSL) followed with a 45.93% rise. Its bile duct cancer device entered final FDA review in the US, with a decision expected in about 45 days, and the company also joined a European trial that could save about $9 million in study costs. Imugene (ASX:IMU) gained 39.18% after reporting two complete responses in patients whose lymphoma had resisted earlier treatment. In plain terms, two patients in separate disease groups saw no detectable cancer after treatment in the early trial.

Cancer names drove the strongest buying

Several of the week’s biggest moves came from cancer drug and device companies. Neuren Pharmaceuticals (ASX:NEU) rose 37.21% after its partner won a positive opinion in Europe for DAYBU in Rett syndrome. Investors focused on the chance of milestone cash, with Neuren due to receive US$35 million on the first European sale. The stock reopened higher and then kept climbing, which suggests buyers did not treat the news as a one-day spike.

AdAlta (ASX:1AD) added 33.33% after paying a US$1 million milestone that unlocks new clinical data and manufacturing materials for its lead cell therapy. Saluda Medical (ASX:SLD) rose 30.00% on FDA approval for a new spinal cord stimulation lead in the US. Neurotech International (ASX:NTI) climbed 30.77% after US patent allowances extended expected protection for NTI164 out to 2042. Investors usually pay close attention to patents because they can help stop direct copycat products for years.

Clarity Pharmaceuticals (ASX:CU6) also had a strong week, up 21.76%, after new prostate cancer imaging and therapy data were slated for presentation in Europe. The stock reopened higher and then attracted more buying during the week. That sort of move often means investors think the new data could help future sales or support later-stage trials.

FDA clearances and trial steps stayed front and centre

Regulatory news kept feeding gains across the sector. Telix Pharmaceuticals (ASX:TLX) rose 10.11% after the FDA agreed on the next part of its Phase 3 prostate cancer trial. A Phase 3 trial is a large study designed to show whether a treatment works well enough and safely enough for approval. Mesoblast (ASX:MSB) gained 9.28% after receiving a filing number from the FDA for rexlemestrocel-L, which means its application has moved into the formal review system.

Imricor Medical Systems (ASX:IMR) advanced 6.70% after FDA clearances for paediatric use of its NorthStar system and Vision-MR catheter. That matters because it opens a path into children’s heart procedures in the US without using radiation. Orthocell (ASX:OCC) slipped only slightly for the week at 0.66%, despite a gap on reopening, after signing a Thai distribution deal for nerve repair product Remplir. Early gains faded, which can happen when investors like the strategic news but want proof of sales before pushing the shares higher.

Revenue growth and commercial proof mattered too

Not all of the action came from drug development. Aroa Biosurgery (ASX:ARX) reported FY26 revenue of NZ$103.9 million, up 23%, and posted its second straight year of positive normalised EBITDA. EBITDA is a rough measure of operating earnings before interest, tax and some non-cash costs. Investors use it to judge whether the core business is making money. The stock still fell 3.39% for the week, which suggests some investors may have focused on FY27 margin guidance or simply locked in earlier gains.

Biome Australia (ASX:BIO) rose 16.33% after posting record FY26 sales of $23.9 million, up 30%. Radius Care (NZX:RAD) gained 5.26% as profit before tax rose 37% and the dividend increased. Cyclopharm (ASX:CYC) edged down 1.00% even after record half-year revenue, because investors also had to absorb a delay to its short-term US installation target. In simple terms, sales are growing, but the hoped-for rollout speed in the US has slipped.

Echo IQ (ASX:EIQ) had two important updates and finished up 3.77%. It raised about $110 million for US expansion and signed an exclusive deal giving it access to up to one million heart scan studies for training its artificial intelligence tools. More data can improve AI products, but investors will still want to see whether the company can turn that larger dataset into paid hospital use.

Funding remained selective, and weak balance sheets still worried investors

Some smaller names rose on new cash or contract wins. Algorae Pharmaceuticals (ASX:1AI) jumped 22.73% after securing a NSW Health supply role and validating its drug-matching software in preclinical work. The stock reopened strongly and then kept moving higher, but the hospital contract is non-exclusive and does not yet give a clear revenue number. Memphasys (ASX:MEM) gained 14.29% on a Thailand IVF distribution deal, while Talius (ASX:TAL) won a $1.15 million aged care contract.

At the other end of the spectrum, TruScreen Group (NZX:TRU) fell 14.29%. Its revenue grew, but the auditor warned there is material uncertainty about whether the company can continue without more funding. TruScreen also issued nearly 150 million new shares in a rights raise, increasing its share count by 17.4%. That can worry investors because each existing share then represents a smaller slice of the company. Chimeric Therapeutics (ASX:CHM) lost 10.77% after launching a strategic review. Reviews can lead to deals, but they can also signal that management is struggling to lift value through normal operations.